Cartesian Therapeutics (RNAC) Receivables - Net (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Receivables - Net of $261000.0 for Q1 2026, down 85.21% year-over-year from $1.8 million in Q1 2025, and down 76.59% quarter-over-quarter from $1.1 million in Q4 2025.
Cartesian Therapeutics (RNAC) Receivables - Net (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Receivables - Net for 12 consecutive years, with $261000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 85.21% year-over-year to $261000.0; the TTM figure through Mar 2026 stood at $261000.0 (down 85.21% YoY), while the FY2025 annual figure was $1.1 million, up 27.87% from the prior year.
- Receivables - Net declined to $261000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $32.0 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
- Historically, Receivables - Net has averaged $6.6 million across 5 years, with a median of $4.9 million in 2023.
- Annual changes were most pronounced in 2024 — Receivables - Net jumped 494.97% — and 2025, when it tumbled 98.9%.
- Cartesian Therapeutics' Receivables - Net stood at $6.6 million in 2022, then fell by 11.01% to $5.9 million in 2023, then tumbled by 85.14% to $872000.0 in 2024, then increased by 27.87% to $1.1 million in 2025, then plunged by 76.59% to $261000.0 in 2026.
- Business Quant data shows RNAC's Receivables - Net at $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196,000.00 |
| Jun 30, 2026 | 196,000.00 |
| Mar 31, 2026 | 261,000.00 |
| Mar 31, 2026 | 261,000.00 |
| Dec 31, 2025 | 1.12 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 722,000.00 |
| Sep 30, 2025 | 722,000.00 |
| Jun 30, 2025 | 354,000.00 |
| Jun 30, 2025 | 354,000.00 |
| Mar 31, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 872,000.00 |
| Dec 31, 2024 | 872,000.00 |
| Sep 30, 2024 | 4.83 Mn |
| Sep 30, 2024 | 4.83 Mn |
| Jun 30, 2024 | 32.04 Mn |
| Jun 30, 2024 | 32.04 Mn |
| Mar 31, 2024 | 2.01 Mn |
| Mar 31, 2024 | 2.01 Mn |